Iovance Biotherapeutics
Stock Forecast, Prediction & Price Target
Iovance Biotherapeutics Financial Estimates
Iovance Biotherapeutics Revenue Estimates
Iovance Biotherapeutics EBITDA Estimates
Iovance Biotherapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $1.18M 0% | Avg: $391.34M Low: $122.72M High: $559.88M avg. 32813.84% | Avg: $694.42M Low: $198.21M High: $1.02B avg. 77.44% | Avg: $1.04B Low: $297.74M High: $1.54B avg. 50.21% | Avg: $1.37B Low: $392.37M High: $2.03B avg. 31.78% |
Net Income
% change YoY
| $-327.82M N/A | $-389.92M -18.94% | $-444.03M -13.87% | Avg: $-231.24M Low: $-357.39M High: $75.24M avg. 47.92% | Avg: $-38.33M Low: $-270.40M High: $284.50M avg. 83.42% | Avg: $183.79M Low: $13.06M High: $298.44M avg. 579.48% | Avg: $366.80M Low: $26.07M High: $595.60M avg. 99.57% |
EBITDA
% change YoY
| $-342.70M N/A | $-398.87M -16.39% | $-427.43M -7.15% | Avg: $234.80M Low: $73.63M High: $335.92M avg. 154.93% | Avg: $416.65M Low: $118.93M High: $616.57M avg. 77.44% | Avg: $625.86M Low: $178.64M High: $926.17M avg. 50.21% | Avg: $824.77M Low: $235.42M High: $1.22B avg. 31.78% |
EPS
% change YoY
| -$2.14 N/A | -$2.45 -14.48% | -$1.89 22.85% | Avg: -$0.71 Low: -$1.52 High: $0.32 avg. 62.32% | Avg: -$0.03 Low: -$1.15 High: $1.21 avg. 95.58% | Avg: $0.78 Low: $0.06 High: $1.27 avg. 2587.01% | Avg: $1.56 Low: $0.11 High: $2.53 avg. 99.57% |
Operating Expenses
% change YoY
| $342.70M N/A | $398.87M 16.39% | $450.99M 13.06% | Avg: $5.87B Low: $1.84B High: $8.41B avg. 1203.43% | Avg: $10.43B Low: $2.97B High: $15.43B avg. 77.44% | Avg: $15.66B Low: $4.47B High: $23.18B avg. 50.21% | Avg: $20.64B Low: $5.89B High: $30.55B avg. 31.78% |
FAQ
What is Iovance Biotherapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 202.60% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -357.39M, average is -231.24M and high is 75.24M.
What is Iovance Biotherapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8243.32% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $122.72M, average is $391.34M and high is $559.88M.
What is Iovance Biotherapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 711.12% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$1.52, average is -$0.71 and high is $0.32.
What is the best performing analyst?
In the last twelve months analysts have been covering Iovance Biotherapeutics stock. The most successful analyst is David Dai.